AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03992729 — intervention group
Intervention type: DRUG
Intervention: Pregnant women not exposed to tildrakizumab
Description: Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
Study NCT00586131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ammonium chloride or sodium citrate/citric acid
Description: Dose dictated by changes in pH
Study NCT00586131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium citrate/citratic acid
Description: dictated by pH
Study NCT04208568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Four ports laparoscopic cholecystectomy under general anaesthesia
Study NCT04012125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible thoracolumbar brace
Description: Subjects would wear the flexible thoracolumbar brace over 18 hours a day
Study NCT01066000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
Study NCT02562768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally
Study NCT02562768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01422252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigi'Fall®
Description: Precocious fall detection device
Study NCT02755298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Study NCT02755298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04209881 — intervention group
Intervention type: OTHER
Intervention: ovarian reserve for Ankylosing spondylitis and control groups
Description: Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded.
Study NCT04994262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Lozenge
Description: In the study, Oka Menthol, a herbal lozenge produced by Otacı, will be used. Its formula contains: menthol 0.26%, eucalyptol 0.065%, thymol 0.0002%, camphor 0.0002%, anise oil, thyme oil, coltsfoot, marshmallow flower, bovine tail flower extracts, glucose and sucrose.~Medical properties: Otacı Oka Menthol Pastil shows antibacterial and fungicidal properties with eucalyptol in its composition. Menthol is effective against local anesthetic, local antitussive and irritation. It also plays a mild analgesic role with camphor in its content. It has an antibacterial and antifungal effect with thymol, a phenolic antiseptic. Otaco Oka Menthol Pastilles also contain extracts of coltsfoot, cow's tail flower and marshmallow flower which are anti-irritant and expectorant.
Study NCT03049696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENCOURAGEING START
Description: 16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
Study NCT02931149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Submucosal injection with PRP was performed prior to endoscopic resection
Study NCT01672762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study NCT02731521 — intervention group
Intervention type: DEVICE
Intervention: 3 Tesla Scanning
Description: Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
Study NCT02731521 — intervention group
Intervention type: DEVICE
Intervention: 7 Tesla Scanning
Description: Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
Study NCT03458897 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serial functional magnetic resonance imaging (MRI)
Description: All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
Study NCT03486743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video on LARC
Description: Participants will watch a short educational video on long acting reversible contraceptive or LARC
Study NCT02022462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Navigation
Description: Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention.
Study NCT02022462 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Navigation
Description: Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention.
Study NCT03107702 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: melatonin
Description: the relationship between melatonin level and analgesia requirement.
Study NCT00182520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 25 mg - 400 mg/day x 12 weeks
Study NCT00182520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 25 - 400 mg/day x 12 weeks
Study NCT01571921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction
Description: Single oral TRF or Gamma-Delta Tocotrienol dosage
Study NCT01571921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction
Description: Single oral TRF or Gamma-Delta Tocotrienol dosage
Study NCT03688828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: 500mg bid
Study NCT03688828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg bid
Study NCT03688828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg bid
Study NCT03688828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1.0g bid
Study NCT03688828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1.0g bid
Study NCT03688828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid
Study NCT03688828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 0.5g bid
Study NCT03688828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.22g bid
Study NCT03688828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.22g bid
Study NCT03570892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Description: Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
Study NCT03690856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inflammatory, neuropsychological and neuroimaging assessment
Description: Acts add by research:~pregnancy test; Centralized: IL1, IL6, TNF~Neuropsychologic tests at M6 and M24:~Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)
Study NCT03813056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glanatec
Description: Rho kinase Inhibitor
Study NCT03813056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optive, Ophthalmic Solution
Description: artificial tears (placebo)
Study NCT03813056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemet Membrane Endothelial Keratoplasty
Description: Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
Study NCT03813056 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Descemet Membrane Endothelial Keratoplasty
Description: Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
Study NCT04399707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) unit
Description: Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
Study NCT04399707 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation (TENS) unit
Description: Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
Study NCT00552734 — intervention group
Intervention type: DEVICE
Intervention: Insulin Guidance Software
Description: At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
Study NCT03794804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ColdZyme
Description: ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
Study NCT03794804 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ColdZyme Placebo
Description: The placebo mouth spray solution has the following composition: ethanol (\<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
Study NCT00507208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint Trismus System
Description: The Dynasplint System will be used for 6 months.
Study NCT00507208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tongue Depressors
Description: Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
Study NCT02786927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaler Preference Questionnaire Version 2
Description: Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
Study NCT02608424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)
Description: The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
Study NCT03481855 — intervention group
Intervention type: DEVICE
Intervention: Lower-body-low-pressure chamber
Description: The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.
Study NCT01436643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
Study NCT01436643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
Study NCT01436643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
Study NCT01436643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
Study NCT02296957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosedative discontinuation
Description: Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
Study NCT05179161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone crawl positioning
Description: Breast cancer patients are placed in a prone position with the ipsilateral arm besides the body rather than extended besides the head on a dedicated couch that provides the required support for maintaining this position.
Study NCT02124473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathy
Study NCT02124473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01023919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)
Description: Cypher stent or YinYi stent randomly implanted in coronary artery disease
Study NCT03697733 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fractional curettage
Description: Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
Study NCT03697733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fractional curettage
Description: Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
Study NCT02862327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous dexamethasone
Description: intravenous injection of dexamethasone
Study NCT02862327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous placebo
Description: intravenous injection of placebo
Study NCT02862327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perineural ropivacaine
Description: brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
Study NCT02862327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: perineural ropivacaine
Description: brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
Study NCT02862327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guidance
Description: ultrasound guidance for brachial plexus block in the axillary fossa
Study NCT02862327 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound guidance
Description: ultrasound guidance for brachial plexus block in the axillary fossa
Study NCT04582877 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FFR measurement
Description: FFR is measured sequentially with the test article and the predicate device.
Study NCT01328587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
Study NCT05173571 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)
Description: Identification of patient needs and non-pharmacological holistic approach, including education, emotion and nutrition (nurse) and optimization of physical activity (respiratory physiotherapist)
Study NCT03530553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hunt Motivational Scale
Description: The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
Study NCT04969822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iDAScore®
Description: A system that studies time lapse images obtained from the embryo culture system, Embryoscope, throughout the development to blastocyst. The system uses data acquired from a sequence of embryo images and has taught itself to identify the embryos with the highest likelihood of implanting and leading to fetal heart-beat detection.
Study NCT03639441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
Study NCT03639441 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction.
Study NCT03936829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
Study NCT02475031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAP-C
Description: TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.